Biogen is once again under fire for its controversial new Alzheimer's drug Aduhelm, but this time because of an ad campaign. The online quiz published by Biogen and Eisai, a Japanese company which is co-promoting the drug, asks questions regarding a person's cognitive health. Doctors at the hospital will be able to prescribe Aduhelm to patients, but they will have to go elsewhere to receive the drug. It was previously recommended to all Alzheimer's patients. A survey of neurologists by Spherix Global Insights found that neurologists only believe the drug is adequate for use in one-in-seven Alzheimer's patients.

Source: The Nation July 23, 2021 19:02 UTC